Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Recent progress in therapy for chronic myelogenous leukemia]

A Urabe1

  • 1Division of Hematology, Kanto Teishin Hospital, Tokyo, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 1, 1997
PubMed
Summary

Chronic myelogenous leukemia (CML) involves hematopoietic stem cell abnormalities. Interferon (IFN) treatment offers improved survival rates for CML patients when bone marrow transplant is not an option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical-study of multiple-myeloma in the elderly.

Oncology reports·2011
Same author

The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab.

American journal of hematology·2007
Same author

Grading system of lymphatic invasion according to D2-40 immunostaining is useful for the prediction of nodal metastasis in squamous cell carcinoma of the uterine cervix.

Histopathology·2006
Same author

Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2004
Same author

Clinical features of the neutropenic host: definitions and initial evaluation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2004
Same author

[Successful treatment of idiopathic pure red cell aplasia with antithymocyte globulin].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2002

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Context:

  • Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm characterized by specific genetic abnormalities.
  • Pathophysiology involves the Philadelphia chromosome (Ph1) and BCR/ABL fusion genes in hematopoietic stem cells.
  • CML affects leukocytes, erythrocytes, and platelets, leading to significant morbidity.

Purpose:

  • To outline the pathophysiology of Chronic Myelogenous Leukemia (CML).
  • To review current treatment modalities for CML, including bone marrow transplantation and interferon (IFN) therapy.
  • To highlight the efficacy of IFN in managing CML, particularly when transplantation is not feasible.

Summary:

  • CML arises from stem cell abnormalities driven by the Philadelphia chromosome and BCR/ABL genes.
  • Treatment options include bone marrow transplantation for younger patients with HLA-matched donors.
  • Interferon (IFN) is the preferred treatment when transplantation is contraindicated, potentially reducing Ph1 chromosome presence.
  • IFN therapy demonstrates superior survival rates compared to conventional chemotherapy like hydroxyurea or busulfan.

Impact:

  • Interferon (IFN) administration significantly improves survival rates in Chronic Myelogenous Leukemia (CML) patients.
  • IFN offers a viable therapeutic alternative for CML patients unsuitable for bone marrow transplantation.
  • Understanding CML pathophysiology guides the development of targeted and effective treatment strategies.

Related Experiment Videos